Unblinding of trial participants to their treatment allocation: Lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Clinical Trials

Volumn 2, Issue 3, 2005, Pages 254-259

  Dinnett, Eleanor M ^a   Mungall, Moira M B ^a   Kent, Jane A ^a   Ronald, Elizabeth S ^a   McIntyre, Karen E ^a   Anderson, Elizabeth ^b   Gaw, Allan ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DOUBLE BLIND PROCEDURE; GERIATRIC PATIENT; HUMAN; INFORMATION DISSEMINATION; METHODOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIAL PARTICIPANT UNBLINDING;

AGED; ANTICHOLESTEREMIC AGENTS; ATTITUDE TO HEALTH; CHOLESTEROL; DISCLOSURE; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT RIGHTS; PATIENT SELECTION; PHYSICIANS, FAMILY; PLACEBOS; PRAVASTATIN; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS; VASCULAR DISEASES;

EID: 21344447311     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774505cn089oa     Document Type: Article

References (15)

1. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002; 359: 696-700.
2. Eli Lilly and Company Clinical Trials Registry. http://www.lillytrials. coni/glossaryA_E.shtml (accessed 6 January 2004).
3. Di Blasi Z, Kaptchuk TJ, Weinman J, Kleijnen J. Informing participants of allocation to placebo at trial closure: postal survey. Brit Med J 2002; 325: 1329-31.
4. Research governance framework for health and social care. www.dh.gov.uk/assetRoot/04/01/47/57/ 04014757.pdf (accessed 28 January 2004).
5. Research governance framework for health and community care. www.show.scot.nhs.uk/cso/ResGov/ Framework/ResGov31oct.doc (accessed 28 January 2004).
6. Research: the role and responsibilities of doctors. General Medical Council. London, 2002.
7. Snowdon C, Garcia J, Elbourne D. Reactions of participants to the results of a randomised controlled trial: exploratory study. BMJ 1998; 317: 21-26.
8. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
9. Shepherd J, Blauw GJ, Murphy MB et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999; 84: 1192-97.
10. Ford I, Blauw GJ, Murphy MB et al. A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med 2002; 3: 8.
11. Dinnett EM, Mungall MMB, Kent JA, Ronald ES, Gaw A. Closing out a large clinical trial: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Clinical Trials 2004; 1: 545-52.
12. Tolmie E, Mungall MMB, Louden G, Lindsay GM, Gaw A for the PROSPER Group. Understanding why older people participate in clinical trials: the experiences of the Scottish PROSPER participants. Age Ageing 2004; 33: 374-378.
13. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.
14. Pomphrey E, Whitehouse A. The finishing touches. Closing a trial (WOSCOPS). Good Clin Pract J 1997; 4: 20-24.
15. Access to Health Records Act 1990 (c.23) HMSO, London.